Brent Richard Stranix

This inventor holds 20 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 9 EPO patents, primarily in HIV Protease Inhibitors. Top assignees: Pharmacor Inc., Ambrilia Biopharma, Inc., Taimed Biologics, Inc.. Active years: 2002-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brent Richard Stranix. Retrieved from https://idiyas.com/inventor/brent-richard-stranix

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 1)

% Patents Active = 60.0

CIPO Patents = 2

EPO Patents = 9 (Patent Applications = 2)

Average Co-Inventor Count = 3.7

ph-index = 8

Forward Citations = 91(Granted Patents)

Location History:

Point-Claire, CA (2013)
Pointe-Claire, CA (2002 - 2024)

Company Filing History:

Ambrilia Biopharma, Inc.

patents

4 out of 5

Taimed Biologics, Inc.

patents

4. 2 out of 4

Montreal Heart Institute

patents

5. 1 out of 1

Taimed Biologies, Inc.

patent

Years Active: 2002-2024

Loading Chart...

Areas of Expertise:

HIV Protease Inhibitors

Cholesterol Treatment

Pyridoxine Derivatives

Amino Acid Derivatives

Aspartyl Protease Inhibitors

Integrase Inhibitors

Prodrugs

Lysine-Based Compounds

Urea Derivatives

Protease Inhibitors

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11931348 - Methods of treating elevated plasma cholesterol (2024-03-19),

2. 11400082 - Methods of treating elevated plasma cholesterol (2022-08-02),

3. 8742158 - Protease inhibitors (2014-06-03),

4. 8742123 - HIV integrase inhibitors from pyridoxine (2014-06-03),

5. 8664248 - Derivatives of pyridoxine for inhibiting HIV integrase (2014-03-04),

6. 8580995 - Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation (2013-11-12),

7. 8410300 - Protease inhibitors (2013-04-02),

8. 8283366 - Derivatives of pyridoxine for inhibiting HIV integrase (2012-10-09),

9. 8227450 - Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation (2012-07-24),

10. 8008297 - Lysine based compounds (2011-08-30),

11. 7388008 - Lysine based compounds (2008-06-17),

12. 6677367 - HIV protease inhibitors based on amino acid derivatives (2004-01-13),

13. 6656965 - HIV protease inhibitors based on amino acid derivatives (2003-12-02),

14. 6638921 - Pyridoxal-5-phosphate derivatives as HIV integrase inhibitors (2003-10-28),

15. 6632816 - Aromatic derivatives as HIV aspartyl protease inhibitors (2003-10-14),

Title: Innovations and Contributions of Brent Richard Stranix

Introduction

Brent Richard Stranix, an acclaimed inventor based in Pointe-Claire, Canada, has made significant contributions to the field of pharmaceuticals. With an impressive portfolio of 20 patents, Stranix's work focuses on innovative methods to tackle elevated cholesterol levels in plasma, showcasing his commitment to advancing health sciences.

Latest Patents

One of Stranix's latest patents involves "Methods of treating elevated plasma cholesterol," which relates to compounds of Formula I. These compounds, along with their pharmaceutically acceptable salts, solvates, or formulations, have been shown to significantly increase low-density lipoprotein receptors. Consequently, they are positioned as useful solutions for preventing and treating elevated cholesterol levels.

Career Highlights

Throughout his career, Stranix has held key positions at notable companies such as Pharmacor Inc. and Ambrilia Biopharma, Inc. His expertise in pharmaceutical innovations has been pivotal in driving research and development within these organizations.

Collaborations

Brent Stranix has collaborated with several esteemed colleagues in the industry, including Gilles Sauvé and Abderrahim Bouzide. These partnerships have been instrumental in advancing his research and enhancing the effectiveness of his innovations.

Conclusion

Brent Richard Stranix's extensive experience and notable patents underscore his role as a leading inventor in the pharmaceutical sector. His innovative solutions to health challenges, particularly in cholesterol management, exemplify his dedication to improving patient health outcomes.

Profile summary based on public USPTO records.